NCT00390091撤回2 期
A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus (SLE)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- and confirmed by supporting data. The pharmacodynamic effic will be assessed
研究概览
简要总结
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.
详细描述
STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single
入排标准
- 年龄范围
- 12 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females between 12 and 70 years old.
- •Diagnosis of Systemic Lupus Erythematosus (SLE)
- •Females must be non-pregnant and non-lactating. Females must agree to use adequate birth control methods during the course of the study.
- •Ability to have weekly intravenous (IV) administration of study drug.
排除标准
- •Prior exposure to abetimus sodium within 6 months prior to screening.
- •Patients not on stable medications for 30 days prior to screening.
- •Patients with acute or chronic infections.
研究组 & 干预措施
未命名试验
干预措施: abetimus sodium (LJP 394) (Drug)
结局指标
主要结局
and confirmed by supporting data. The pharmacodynamic effic will be assessed
using historical placebo effect as a control.
patients with SLE will be based on laboratory data from the central laboratory
The assessment of the safety and pharmacodynamic effect of abetimus sodium at
doses of 100mg, 300mg, and 900mg in reducing the anti-dsDNA antibody levels in
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study of Enzalutamide and LY3023414 in Men With Prostate CancerProstate Cancer MetastaticNCT02407054Eli Lilly and Company142
已完成
3 期
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT02265705Eli Lilly and Company290
已完成
2 期
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction ProcedureSedationPainAnxietyNCT00894699Talphera, Inc40
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B VaccineHepatitis B, ChronicNCT04289987CHA Vaccine Institute Co., Ltd.134
已完成
3 期
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02597049Eli Lilly and Company424